Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele™, the First Oral Therap…

ARPA-H award supports the development of an oral prodrug using Seaport’s proprietary Glyph™ platform to address dysfunctional ...
Monash University

Monash University and Seaport Therapeutics Awarded up to $21 Million AUD from ARPA-H to Advance GlyphCeleTM, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function

The project is being led by the Monash Institute of Pharmaceutical Sciences (MIPS) in partnership with long term collaborator, Seaport Therapeutics, and is being backed by up to AUD$21.5M via the ARPA ...

Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA--H to Advance Seaport's GlyphCele(TM), the First Oral Therapeutic ...

Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the award of an up ...